Sunshine Biopharma, Inc.
SBFM
$2.18
$0.041.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.05% | 4.10% | 13.24% | 19.22% | 35.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.05% | 4.10% | 13.24% | 19.22% | 35.51% |
| Cost of Revenue | -5.56% | -0.64% | 9.60% | 14.22% | 40.92% |
| Gross Profit | 5.98% | 14.86% | 21.44% | 30.68% | 24.60% |
| SG&A Expenses | -0.85% | 2.96% | 22.07% | 39.46% | 36.67% |
| Depreciation & Amortization | 40.05% | 48.55% | 48.88% | 54.42% | 56.40% |
| Other Operating Expenses | 16.02% | 21.27% | 27.21% | 10.57% | 39.55% |
| Total Operating Expenses | -4.46% | 0.36% | 11.38% | 19.13% | 34.99% |
| Operating Income | 19.79% | 22.28% | 1.10% | -18.47% | -31.79% |
| Income Before Tax | -12.21% | -10.89% | -58.28% | -72.99% | -43.36% |
| Income Tax Expenses | 120.78% | 109.20% | -551.40% | -171.50% | -180.08% |
| Earnings from Continuing Operations | -20.07% | -16.38% | -41.81% | -71.39% | -23.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.07% | -16.38% | -41.81% | -71.39% | -23.06% |
| EBIT | 19.79% | 22.28% | 1.10% | -18.47% | -31.79% |
| EBITDA | 22.48% | 25.14% | 3.24% | -17.06% | -30.86% |
| EPS Basic | 71.02% | 76.04% | 59.83% | 31.59% | -117.14% |
| Normalized Basic EPS | 61.54% | 72.55% | 35.17% | -24.70% | -14.32% |
| EPS Diluted | 71.02% | 76.04% | 59.83% | 31.59% | -117.14% |
| Normalized Diluted EPS | 61.54% | 72.55% | 35.17% | -24.70% | -14.32% |
| Average Basic Shares Outstanding | 291.63% | 248.54% | 499.79% | 1,172.54% | 471.42% |
| Average Diluted Shares Outstanding | 233.30% | 201.00% | 348.96% | 536.27% | 571.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |